Loading…
Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection
Background and Aims Albinterferon is a fusion of albumin and interferon‐α2b developed to improve the pharmacokinetics, convenience, and potential efficacy of interferon‐α for the treatment of chronic hepatitis infections. Methods This open‐label, randomized, active‐controlled, multicenter study inve...
Saved in:
| Published in: | Journal of gastroenterology and hepatology 2015-01, Vol.30 (1), p.184-191 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3631-34205b5ac04537ae391155f3e095930734a7d836006232d95b919e3a2a42de723 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3631-34205b5ac04537ae391155f3e095930734a7d836006232d95b919e3a2a42de723 |
| container_end_page | 191 |
| container_issue | 1 |
| container_start_page | 184 |
| container_title | Journal of gastroenterology and hepatology |
| container_volume | 30 |
| creator | Colvin, Richard A Tanwandee, Tawesak Piratvisuth, Teerha Thongsawat, Satawat Hui, Aric Josun Zhang, Hongfei Ren, Hong Chen, Pei-Jer Chuang, Wan-Long Sobhonslidsuk, Abhasnee Li, Ruobing Qi, Yin Praestgaard, Jens Han, Yi Xu, Junfang Stein, Daniel S |
| description | Background and Aims
Albinterferon is a fusion of albumin and interferon‐α2b developed to improve the pharmacokinetics, convenience, and potential efficacy of interferon‐α for the treatment of chronic hepatitis infections.
Methods
This open‐label, randomized, active‐controlled, multicenter study investigated the safety and efficacy of albinterferon in patients with chronic hepatitis B virus (HBV) infection who were e‐antigen (HBeAg) positive. One hundred and forty‐one patients received one of four albinterferon doses/regimens or pegylated‐interferon‐α2a. Primary efficacy outcomes were changes in serum HBeAg and antibody, HBV‐DNA, and alanine aminotransferase. Principal safety outcomes were changes in laboratory values, pulmonary function, and adverse events.
Results
The study was prematurely terminated as phase III trials in hepatitis C infection indicated noninferior efficacy but inferior safety compared with pegylated‐interferon‐α2a. Here, all treatment groups had a significant reduction in HBV‐DNA from baseline. Reductions in HBV‐DNA were not significantly different, except the 1200 μg every 4 weeks albinterferon dose which was inferior compared with pegylated‐interferon‐α2a. The serum alanine aminotransferase levels decreased in all arms. The per‐patient incidence of adverse events was not significantly different for albinterferon (96.4–100%) and pegylated‐interferon‐α2a (93.1%). Total adverse events, however, were higher for albinterferon and correlated to dose. Decreased lung function was found in all arms (∼93% of patients), and was more common in some albinterferon groups.
Conclusions
Albinterferon doses with similar anti‐HBV efficacy to pegylated‐interferon‐α2a had higher rates of certain adverse events, particularly changes in lung diffusion capacity (http://www.clinicaltrials.gov number NCT00964665). |
| doi_str_mv | 10.1111/jgh.12671 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1640480071</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1640480071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3631-34205b5ac04537ae391155f3e095930734a7d836006232d95b919e3a2a42de723</originalsourceid><addsrcrecordid>eNp1kEFPFDEYhhujgQU5-AdMj5ow0E7b6fYoRBYNYqIQj023841TmGnXtissd_43XRf2Zi9Nnu9538OL0DtKjmh5xze_-yNaN5K-QhPKOamo5M1rNCFTKirFqNpFeyndEEI4kWIH7dZcKSGomKDHH8a3YXQP0B5iG3yOYRigxYvexNHYcOs8ZGdxsbasXXkzFgZ_zbA02QWPQ4fNMHc-Q-wgFuA8XpQT-Jzwncs9tn3BJdTDmmeX8EmROrDr_Fv0pjNDgoPnfx9dn32-Oj2vLr7Pvpx-uqgsaxitGK-JmAtjCRdMGmCKUiE6BkQJxYhk3Mh2yhpCmprVrRJzRRUwUxtetyBrto8-bHoXMfxZQsp6dMnCMBgPYZk0bTjhU0IkLerHjWpjSClCpxfRjSauNCV6vbouq-t_qxf3_XPtcj5CuzVfZi7C8Ua4cwOs_t-kv87OXyqrTcKlDPfbhIm3upFMCv3rcqan9Fujfp6c6Uv2BOvUnD4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1640480071</pqid></control><display><type>article</type><title>Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Colvin, Richard A ; Tanwandee, Tawesak ; Piratvisuth, Teerha ; Thongsawat, Satawat ; Hui, Aric Josun ; Zhang, Hongfei ; Ren, Hong ; Chen, Pei-Jer ; Chuang, Wan-Long ; Sobhonslidsuk, Abhasnee ; Li, Ruobing ; Qi, Yin ; Praestgaard, Jens ; Han, Yi ; Xu, Junfang ; Stein, Daniel S</creator><creatorcontrib>Colvin, Richard A ; Tanwandee, Tawesak ; Piratvisuth, Teerha ; Thongsawat, Satawat ; Hui, Aric Josun ; Zhang, Hongfei ; Ren, Hong ; Chen, Pei-Jer ; Chuang, Wan-Long ; Sobhonslidsuk, Abhasnee ; Li, Ruobing ; Qi, Yin ; Praestgaard, Jens ; Han, Yi ; Xu, Junfang ; Stein, Daniel S ; ABF656A2206 Study Group ; the ABF656A2206 Study Group</creatorcontrib><description>Background and Aims
Albinterferon is a fusion of albumin and interferon‐α2b developed to improve the pharmacokinetics, convenience, and potential efficacy of interferon‐α for the treatment of chronic hepatitis infections.
Methods
This open‐label, randomized, active‐controlled, multicenter study investigated the safety and efficacy of albinterferon in patients with chronic hepatitis B virus (HBV) infection who were e‐antigen (HBeAg) positive. One hundred and forty‐one patients received one of four albinterferon doses/regimens or pegylated‐interferon‐α2a. Primary efficacy outcomes were changes in serum HBeAg and antibody, HBV‐DNA, and alanine aminotransferase. Principal safety outcomes were changes in laboratory values, pulmonary function, and adverse events.
Results
The study was prematurely terminated as phase III trials in hepatitis C infection indicated noninferior efficacy but inferior safety compared with pegylated‐interferon‐α2a. Here, all treatment groups had a significant reduction in HBV‐DNA from baseline. Reductions in HBV‐DNA were not significantly different, except the 1200 μg every 4 weeks albinterferon dose which was inferior compared with pegylated‐interferon‐α2a. The serum alanine aminotransferase levels decreased in all arms. The per‐patient incidence of adverse events was not significantly different for albinterferon (96.4–100%) and pegylated‐interferon‐α2a (93.1%). Total adverse events, however, were higher for albinterferon and correlated to dose. Decreased lung function was found in all arms (∼93% of patients), and was more common in some albinterferon groups.
Conclusions
Albinterferon doses with similar anti‐HBV efficacy to pegylated‐interferon‐α2a had higher rates of certain adverse events, particularly changes in lung diffusion capacity (http://www.clinicaltrials.gov number NCT00964665).</description><identifier>ISSN: 0815-9319</identifier><identifier>EISSN: 1440-1746</identifier><identifier>DOI: 10.1111/jgh.12671</identifier><identifier>PMID: 24995515</identifier><language>eng</language><publisher>Australia: Blackwell Publishing Ltd</publisher><subject>Adult ; Alanine Transaminase - blood ; albinterferon ; Albumins - administration & dosage ; Albumins - adverse effects ; Antiviral Agents - administration & dosage ; Antiviral Agents - adverse effects ; Biomarkers - blood ; DNA, Viral - blood ; Female ; hepatitis B ; Hepatitis B e Antigens - blood ; Hepatitis B virus - genetics ; Hepatitis B virus - immunology ; Hepatitis B, Chronic - diagnosis ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - virology ; Humans ; Interferon-alpha - administration & dosage ; Interferon-alpha - adverse effects ; lung diffusion capacity ; Male ; Polyethylene Glycols - administration & dosage ; Polyethylene Glycols - adverse effects ; Recombinant Proteins - administration & dosage ; Recombinant Proteins - adverse effects ; Treatment Outcome ; Young Adult</subject><ispartof>Journal of gastroenterology and hepatology, 2015-01, Vol.30 (1), p.184-191</ispartof><rights>2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd</rights><rights>2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3631-34205b5ac04537ae391155f3e095930734a7d836006232d95b919e3a2a42de723</citedby><cites>FETCH-LOGICAL-c3631-34205b5ac04537ae391155f3e095930734a7d836006232d95b919e3a2a42de723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24995515$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Colvin, Richard A</creatorcontrib><creatorcontrib>Tanwandee, Tawesak</creatorcontrib><creatorcontrib>Piratvisuth, Teerha</creatorcontrib><creatorcontrib>Thongsawat, Satawat</creatorcontrib><creatorcontrib>Hui, Aric Josun</creatorcontrib><creatorcontrib>Zhang, Hongfei</creatorcontrib><creatorcontrib>Ren, Hong</creatorcontrib><creatorcontrib>Chen, Pei-Jer</creatorcontrib><creatorcontrib>Chuang, Wan-Long</creatorcontrib><creatorcontrib>Sobhonslidsuk, Abhasnee</creatorcontrib><creatorcontrib>Li, Ruobing</creatorcontrib><creatorcontrib>Qi, Yin</creatorcontrib><creatorcontrib>Praestgaard, Jens</creatorcontrib><creatorcontrib>Han, Yi</creatorcontrib><creatorcontrib>Xu, Junfang</creatorcontrib><creatorcontrib>Stein, Daniel S</creatorcontrib><creatorcontrib>ABF656A2206 Study Group</creatorcontrib><creatorcontrib>the ABF656A2206 Study Group</creatorcontrib><title>Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection</title><title>Journal of gastroenterology and hepatology</title><addtitle>J Gastroenterol Hepatol</addtitle><description>Background and Aims
Albinterferon is a fusion of albumin and interferon‐α2b developed to improve the pharmacokinetics, convenience, and potential efficacy of interferon‐α for the treatment of chronic hepatitis infections.
Methods
This open‐label, randomized, active‐controlled, multicenter study investigated the safety and efficacy of albinterferon in patients with chronic hepatitis B virus (HBV) infection who were e‐antigen (HBeAg) positive. One hundred and forty‐one patients received one of four albinterferon doses/regimens or pegylated‐interferon‐α2a. Primary efficacy outcomes were changes in serum HBeAg and antibody, HBV‐DNA, and alanine aminotransferase. Principal safety outcomes were changes in laboratory values, pulmonary function, and adverse events.
Results
The study was prematurely terminated as phase III trials in hepatitis C infection indicated noninferior efficacy but inferior safety compared with pegylated‐interferon‐α2a. Here, all treatment groups had a significant reduction in HBV‐DNA from baseline. Reductions in HBV‐DNA were not significantly different, except the 1200 μg every 4 weeks albinterferon dose which was inferior compared with pegylated‐interferon‐α2a. The serum alanine aminotransferase levels decreased in all arms. The per‐patient incidence of adverse events was not significantly different for albinterferon (96.4–100%) and pegylated‐interferon‐α2a (93.1%). Total adverse events, however, were higher for albinterferon and correlated to dose. Decreased lung function was found in all arms (∼93% of patients), and was more common in some albinterferon groups.
Conclusions
Albinterferon doses with similar anti‐HBV efficacy to pegylated‐interferon‐α2a had higher rates of certain adverse events, particularly changes in lung diffusion capacity (http://www.clinicaltrials.gov number NCT00964665).</description><subject>Adult</subject><subject>Alanine Transaminase - blood</subject><subject>albinterferon</subject><subject>Albumins - administration & dosage</subject><subject>Albumins - adverse effects</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - adverse effects</subject><subject>Biomarkers - blood</subject><subject>DNA, Viral - blood</subject><subject>Female</subject><subject>hepatitis B</subject><subject>Hepatitis B e Antigens - blood</subject><subject>Hepatitis B virus - genetics</subject><subject>Hepatitis B virus - immunology</subject><subject>Hepatitis B, Chronic - diagnosis</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - virology</subject><subject>Humans</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Interferon-alpha - adverse effects</subject><subject>lung diffusion capacity</subject><subject>Male</subject><subject>Polyethylene Glycols - administration & dosage</subject><subject>Polyethylene Glycols - adverse effects</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Recombinant Proteins - adverse effects</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0815-9319</issn><issn>1440-1746</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1kEFPFDEYhhujgQU5-AdMj5ow0E7b6fYoRBYNYqIQj023841TmGnXtissd_43XRf2Zi9Nnu9538OL0DtKjmh5xze_-yNaN5K-QhPKOamo5M1rNCFTKirFqNpFeyndEEI4kWIH7dZcKSGomKDHH8a3YXQP0B5iG3yOYRigxYvexNHYcOs8ZGdxsbasXXkzFgZ_zbA02QWPQ4fNMHc-Q-wgFuA8XpQT-Jzwncs9tn3BJdTDmmeX8EmROrDr_Fv0pjNDgoPnfx9dn32-Oj2vLr7Pvpx-uqgsaxitGK-JmAtjCRdMGmCKUiE6BkQJxYhk3Mh2yhpCmprVrRJzRRUwUxtetyBrto8-bHoXMfxZQsp6dMnCMBgPYZk0bTjhU0IkLerHjWpjSClCpxfRjSauNCV6vbouq-t_qxf3_XPtcj5CuzVfZi7C8Ua4cwOs_t-kv87OXyqrTcKlDPfbhIm3upFMCv3rcqan9Fujfp6c6Uv2BOvUnD4</recordid><startdate>201501</startdate><enddate>201501</enddate><creator>Colvin, Richard A</creator><creator>Tanwandee, Tawesak</creator><creator>Piratvisuth, Teerha</creator><creator>Thongsawat, Satawat</creator><creator>Hui, Aric Josun</creator><creator>Zhang, Hongfei</creator><creator>Ren, Hong</creator><creator>Chen, Pei-Jer</creator><creator>Chuang, Wan-Long</creator><creator>Sobhonslidsuk, Abhasnee</creator><creator>Li, Ruobing</creator><creator>Qi, Yin</creator><creator>Praestgaard, Jens</creator><creator>Han, Yi</creator><creator>Xu, Junfang</creator><creator>Stein, Daniel S</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201501</creationdate><title>Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection</title><author>Colvin, Richard A ; Tanwandee, Tawesak ; Piratvisuth, Teerha ; Thongsawat, Satawat ; Hui, Aric Josun ; Zhang, Hongfei ; Ren, Hong ; Chen, Pei-Jer ; Chuang, Wan-Long ; Sobhonslidsuk, Abhasnee ; Li, Ruobing ; Qi, Yin ; Praestgaard, Jens ; Han, Yi ; Xu, Junfang ; Stein, Daniel S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3631-34205b5ac04537ae391155f3e095930734a7d836006232d95b919e3a2a42de723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Alanine Transaminase - blood</topic><topic>albinterferon</topic><topic>Albumins - administration & dosage</topic><topic>Albumins - adverse effects</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - adverse effects</topic><topic>Biomarkers - blood</topic><topic>DNA, Viral - blood</topic><topic>Female</topic><topic>hepatitis B</topic><topic>Hepatitis B e Antigens - blood</topic><topic>Hepatitis B virus - genetics</topic><topic>Hepatitis B virus - immunology</topic><topic>Hepatitis B, Chronic - diagnosis</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - virology</topic><topic>Humans</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Interferon-alpha - adverse effects</topic><topic>lung diffusion capacity</topic><topic>Male</topic><topic>Polyethylene Glycols - administration & dosage</topic><topic>Polyethylene Glycols - adverse effects</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Recombinant Proteins - adverse effects</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Colvin, Richard A</creatorcontrib><creatorcontrib>Tanwandee, Tawesak</creatorcontrib><creatorcontrib>Piratvisuth, Teerha</creatorcontrib><creatorcontrib>Thongsawat, Satawat</creatorcontrib><creatorcontrib>Hui, Aric Josun</creatorcontrib><creatorcontrib>Zhang, Hongfei</creatorcontrib><creatorcontrib>Ren, Hong</creatorcontrib><creatorcontrib>Chen, Pei-Jer</creatorcontrib><creatorcontrib>Chuang, Wan-Long</creatorcontrib><creatorcontrib>Sobhonslidsuk, Abhasnee</creatorcontrib><creatorcontrib>Li, Ruobing</creatorcontrib><creatorcontrib>Qi, Yin</creatorcontrib><creatorcontrib>Praestgaard, Jens</creatorcontrib><creatorcontrib>Han, Yi</creatorcontrib><creatorcontrib>Xu, Junfang</creatorcontrib><creatorcontrib>Stein, Daniel S</creatorcontrib><creatorcontrib>ABF656A2206 Study Group</creatorcontrib><creatorcontrib>the ABF656A2206 Study Group</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Colvin, Richard A</au><au>Tanwandee, Tawesak</au><au>Piratvisuth, Teerha</au><au>Thongsawat, Satawat</au><au>Hui, Aric Josun</au><au>Zhang, Hongfei</au><au>Ren, Hong</au><au>Chen, Pei-Jer</au><au>Chuang, Wan-Long</au><au>Sobhonslidsuk, Abhasnee</au><au>Li, Ruobing</au><au>Qi, Yin</au><au>Praestgaard, Jens</au><au>Han, Yi</au><au>Xu, Junfang</au><au>Stein, Daniel S</au><aucorp>ABF656A2206 Study Group</aucorp><aucorp>the ABF656A2206 Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection</atitle><jtitle>Journal of gastroenterology and hepatology</jtitle><addtitle>J Gastroenterol Hepatol</addtitle><date>2015-01</date><risdate>2015</risdate><volume>30</volume><issue>1</issue><spage>184</spage><epage>191</epage><pages>184-191</pages><issn>0815-9319</issn><eissn>1440-1746</eissn><abstract>Background and Aims
Albinterferon is a fusion of albumin and interferon‐α2b developed to improve the pharmacokinetics, convenience, and potential efficacy of interferon‐α for the treatment of chronic hepatitis infections.
Methods
This open‐label, randomized, active‐controlled, multicenter study investigated the safety and efficacy of albinterferon in patients with chronic hepatitis B virus (HBV) infection who were e‐antigen (HBeAg) positive. One hundred and forty‐one patients received one of four albinterferon doses/regimens or pegylated‐interferon‐α2a. Primary efficacy outcomes were changes in serum HBeAg and antibody, HBV‐DNA, and alanine aminotransferase. Principal safety outcomes were changes in laboratory values, pulmonary function, and adverse events.
Results
The study was prematurely terminated as phase III trials in hepatitis C infection indicated noninferior efficacy but inferior safety compared with pegylated‐interferon‐α2a. Here, all treatment groups had a significant reduction in HBV‐DNA from baseline. Reductions in HBV‐DNA were not significantly different, except the 1200 μg every 4 weeks albinterferon dose which was inferior compared with pegylated‐interferon‐α2a. The serum alanine aminotransferase levels decreased in all arms. The per‐patient incidence of adverse events was not significantly different for albinterferon (96.4–100%) and pegylated‐interferon‐α2a (93.1%). Total adverse events, however, were higher for albinterferon and correlated to dose. Decreased lung function was found in all arms (∼93% of patients), and was more common in some albinterferon groups.
Conclusions
Albinterferon doses with similar anti‐HBV efficacy to pegylated‐interferon‐α2a had higher rates of certain adverse events, particularly changes in lung diffusion capacity (http://www.clinicaltrials.gov number NCT00964665).</abstract><cop>Australia</cop><pub>Blackwell Publishing Ltd</pub><pmid>24995515</pmid><doi>10.1111/jgh.12671</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0815-9319 |
| ispartof | Journal of gastroenterology and hepatology, 2015-01, Vol.30 (1), p.184-191 |
| issn | 0815-9319 1440-1746 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1640480071 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adult Alanine Transaminase - blood albinterferon Albumins - administration & dosage Albumins - adverse effects Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Biomarkers - blood DNA, Viral - blood Female hepatitis B Hepatitis B e Antigens - blood Hepatitis B virus - genetics Hepatitis B virus - immunology Hepatitis B, Chronic - diagnosis Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - virology Humans Interferon-alpha - administration & dosage Interferon-alpha - adverse effects lung diffusion capacity Male Polyethylene Glycols - administration & dosage Polyethylene Glycols - adverse effects Recombinant Proteins - administration & dosage Recombinant Proteins - adverse effects Treatment Outcome Young Adult |
| title | Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A45%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Randomized,%20controlled%20pharmacokinetic%20and%20pharmacodynamic%20evaluation%20of%20albinterferon%20in%20patients%20with%20chronic%20hepatitis%20B%20infection&rft.jtitle=Journal%20of%20gastroenterology%20and%20hepatology&rft.au=Colvin,%20Richard%20A&rft.aucorp=ABF656A2206%20Study%20Group&rft.date=2015-01&rft.volume=30&rft.issue=1&rft.spage=184&rft.epage=191&rft.pages=184-191&rft.issn=0815-9319&rft.eissn=1440-1746&rft_id=info:doi/10.1111/jgh.12671&rft_dat=%3Cproquest_cross%3E1640480071%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3631-34205b5ac04537ae391155f3e095930734a7d836006232d95b919e3a2a42de723%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1640480071&rft_id=info:pmid/24995515&rfr_iscdi=true |